Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash ...
Recursion Pharmaceuticals (RXRX) closed the last trading session at $8.59, gaining 20% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
That brings us to Recursion Pharmaceuticals (RXRX +5.71%), a biotech company specializing in drug discovery using artificial intelligence (AI). At least one notable name in the investing world thinks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results